Australia's most trusted
source of pharma news
Posted 1 August 2024 AM
A double PBS victory for BMS blockbuster Opdivo which has won reimbursement from today as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) as well as an adjuvant treatment for high-risk muscle invasive urothelial carcinoma after radical resection.
Opdivo with platinum-based chemotherapy is Australia's first neoadjuvant immunotherapy-based option for eligible patients with resectable NSCLC to be listed on the PBS, keeping pace with changes in a fast moving treatment landscape.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.